Clinical trial
A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva®…
NCT00343187 · Allergan, Industry · Terminated
Key facts
| NCT number | NCT00343187 |
|---|---|
| Title | A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash |
| Official title | A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib) |
| Lead sponsor | Allergan, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rash, Non-small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | ACZONE (dapsone) Gel, 5%, Vehicle Control |
| Enrollment | 2 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jun 22, 2006 |
| Last update posted | May 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: